15.12

3.18% 0.49

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $15.12, with a volume of 1.70M. It is up +3.18% in the last 24 hours and up +2.97% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Previous Close:

$14.63

Open:

$14.52

24h Volume:

1.70M

Relative Volume:

0.50

Market Cap:

$3.60B

Revenue:

$474.17M

Net Income/Loss:

$208.93M

P/E Ratio:

17.80

EPS:

0.8493

Net Cash Flow:

$65.61M

1W Performance:

-2.80%

1M Performance:

+2.97%

6M Performance:

-36.33%

1Y Performance:

-19.84%

1-Day Range:

$14.42

$15.10

1-Week Range:

$14.42

$15.76

52-Week Range:

$13.82

$25.67

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1137)

Industry

Biotechnology (635)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

685

Twitter

@AdmaBiologics

Next Earnings Date

2025-03-03

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	15.09	3.49B	474.17M	208.93M	65.61M	0.8493
VRTX Vertex Pharmaceuticals Inc	425.25	107.10B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	636.93	66.00B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	436.57	55.95B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	831.59	51.19B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.78	38.98B	447.02M	-1.18B	-906.14M	-6.1812

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

06:02 AM

108,400 Shares in ADMA Biologics Inc $ADMA Acquired by Homestead Advisers Corp - MarketBeat

06:02 AM

05:08 AM

Hussman Strategic Advisors Inc. Sells 42,000 Shares of ADMA Biologics Inc $ADMA - MarketBeat

05:08 AM

12:36 PM

Can ADMA Biologics Inc. stock attract ESG capital inflowsJuly 2025 Sector Moves & AI Enhanced Trading Alerts - newser.com

12:36 PM

Nov 04, 2025

Applying Wyckoff theory to ADMA Biologics Inc. stockJuly 2025 Intraday Action & Long-Term Investment Growth Plans - newser.com

Nov 04, 2025

Risk adjusted return profile for ADMA Biologics Inc. analyzedJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com

Nov 04, 2025